Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric oxide during cardiopulmonary bypass for congenital heart surgery
2017-004684-12Phase 3Active
- Sponsor
- Queensland Children's Hospital
- Start
- Feb 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nitric oxide in Cardiovascular Malformation (CVM) (2 arms), sponsored by Queensland Children's Hospital. Primary endpoint: Ventilator-free days within 28 days. Started Feb 2019; status: active.
02
Drugs
nitric oxide
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2017-004684-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004684-12.